These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28232654)

  • 21. [Duchenne muscular dystrophy].
    Ishiura S; Sugita H
    No To Shinkei; 1991 May; 43(5):405-9. PubMed ID: 1910927
    [No Abstract]   [Full Text] [Related]  

  • 22. [Molecular therapy of muscular dystrophy].
    Takeda S
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1267-9. PubMed ID: 11464475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A missense mutation in the dystrophin gene in a Duchenne muscular dystrophy patient.
    Prior TW; Papp AC; Snyder PJ; Burghes AH; Bartolo C; Sedra MS; Western LM; Mendell JR
    Nat Genet; 1993 Aug; 4(4):357-60. PubMed ID: 8401582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases.
    Ousterout DG; Kabadi AM; Thakore PI; Perez-Pinera P; Brown MT; Majoros WH; Reddy TE; Gersbach CA
    Mol Ther; 2015 Mar; 23(3):523-32. PubMed ID: 25492562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duchenne muscular dystrophy.
    Matsuo M
    Southeast Asian J Trop Med Public Health; 1995; 26 Suppl 1():166-71. PubMed ID: 8629099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular approaches to therapy for Duchenne and limb-girdle muscular dystrophy.
    Stedman HH
    Curr Opin Mol Ther; 2001 Aug; 3(4):350-6. PubMed ID: 11525558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CRISPR-Editing Therapy for Duchenne Muscular Dystrophy.
    Chemello F; Olson EN; Bassel-Duby R
    Hum Gene Ther; 2023 May; 34(9-10):379-387. PubMed ID: 37060194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New developments in the use of gene therapy to treat Duchenne muscular dystrophy.
    Jarmin S; Kymalainen H; Popplewell L; Dickson G
    Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutics for Duchenne muscular dystrophy: current approaches and future directions.
    Bogdanovich S; Perkins KJ; Krag TO; Khurana TS
    J Mol Med (Berl); 2004 Feb; 82(2):102-15. PubMed ID: 14673527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy.
    Araki E; Nakamura K; Nakao K; Kameya S; Kobayashi O; Nonaka I; Kobayashi T; Katsuki M
    Biochem Biophys Res Commun; 1997 Sep; 238(2):492-7. PubMed ID: 9299538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene-editing, immunological and iPSCs based therapeutics for muscular dystrophy.
    Singh S; Singh T; Kunja C; Dhoat NS; Dhania NK
    Eur J Pharmacol; 2021 Dec; 912():174568. PubMed ID: 34656607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relatively low proportion of dystrophin gene deletions in Israeli Duchenne and Becker muscular dystrophy patients.
    Shomrat R; Gluck E; Legum C; Shiloh Y
    Am J Med Genet; 1994 Feb; 49(4):369-73. PubMed ID: 8160727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of gene deletions by PCR analysis in a Malaysian patient with Duchenne muscular dystrophy.
    Lee MK; Manonmani V; Arahata K
    Med J Malaysia; 1993 Mar; 48(1):46-50. PubMed ID: 8341171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing.
    Zhang Y; Long C; Bassel-Duby R; Olson EN
    Physiol Rev; 2018 Jul; 98(3):1205-1240. PubMed ID: 29717930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strand bias in oligonucleotide-mediated dystrophin gene editing.
    Bertoni C; Morris GE; Rando TA
    Hum Mol Genet; 2005 Jan; 14(2):221-33. PubMed ID: 15563511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunological detection of the dystrophin molecule with antibody directed against the synthetic peptide.
    Ohta M; Ohta K; Hara H; Itoh N; Itagaki Y; Nishitani H; Hayashi K
    Biochem Int; 1991 Dec; 25(6):1087-93. PubMed ID: 1810253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of dystrophin genomic and cDNA probes for solving difficulties in carrier detection and prenatal diagnosis of Duchenne muscular dystrophy.
    Shomrat R; Driks N; Legum C; Shiloh Y
    Am J Med Genet; 1992 Feb; 42(3):281-7. PubMed ID: 1536162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current understanding of dystrophin-related muscular dystrophy and therapeutic challenges ahead.
    Zhou GQ; Xie HQ; Zhang SZ; Yang ZM
    Chin Med J (Engl); 2006 Aug; 119(16):1381-91. PubMed ID: 16934185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dystrophin and muscular dystrophy: past, present, and future.
    O'Brien KF; Kunkel LM
    Mol Genet Metab; 2001; 74(1-2):75-88. PubMed ID: 11592805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation.
    Gussoni E; Pavlath GK; Lanctot AM; Sharma KR; Miller RG; Steinman L; Blau HM
    Nature; 1992 Apr; 356(6368):435-8. PubMed ID: 1557125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.